GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » 3-Year EPS without NRI Growth Rate

Inovio Pharmaceuticals (Inovio Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 7.70% (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Inovio Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-1.14.

During the past 3 years, the average EPS without NRI Growth Rate was 7.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Inovio Pharmaceuticals was 24.70% per year. The lowest was -32.20% per year. And the median was 6.80% per year.


Competitive Comparison of Inovio Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Inovio Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Inovio Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Inovio Pharmaceuticals  (NAS:INO) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Inovio Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Executives
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
David B. Weiner director 717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner officer: Chief Medical Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau officer: Chief Scientific Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea officer: Chief Operating Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies officer: CFO
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim director, officer: Chief Executive Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard director 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno director
Morton Collins director
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai officer: Chief Operating Officer VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422